TikTok claims FDA approved orforglipron - that's wrong
Quick answer
Orforglipron is an experimental oral GLP-1 receptor agonist in Phase 2 development by Eli Lilly. Early results show 12.6% weight loss over 36 weeks, but the drug has not received FDA approval and is years away from market availability.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What does this TikTok video claim?
Nutritionist @nutriletiboettcher tells her 20,000 viewers that "this week the FDA released orforglipron," calling it a new GLP-1 receptor agonist that could be a good alternative for weight maintenance after using Mounjaro (tirzepatide).
She's positioning orforglipron as an already-available treatment option. The timing matters here because people are actively looking for Mounjaro alternatives due to supply issues and cost concerns.
Did the FDA actually approve orforglipron this week?
No, and this is a significant error. The FDA has not approved orforglipron for any indication. What actually happened was Eli Lilly released positive Phase 2 trial results for orforglipron in December 2023, showing 12.6% weight loss at the highest dose over 36 weeks.
Orforglipron is still in clinical development. Lilly expects to start Phase 3 trials in 2024, meaning FDA approval is likely years away, not this week.
This isn't a small mistake about timing. It's telling people a drug is available when it isn't.
What do we actually know about orforglipron's effectiveness?
The Phase 2 GIPR-027 study (not yet published in a peer-reviewed journal) found orforglipron led to placebo-adjusted weight loss of 9.4% at 24mg once daily and 12.6% at 45mg once daily over 36 weeks.
That's decent but not spectacular. For comparison, the SURMOUNT-1 trial found tirzepatide (Mounjaro) produced 20.9% weight loss at 15mg over 72 weeks.
Orforglipron's main advantage isn't superior effectiveness. It's that it's an oral pill, while current GLP-1 drugs require weekly injections.
Could orforglipron work for weight maintenance after Mounjaro?
This is pure speculation at this point. No studies have tested orforglipron specifically for weight maintenance after other GLP-1 drugs, and the creator provides no evidence for this claim.
We know from other GLP-1 research that people typically regain weight when they stop treatment. The STEP 1 extension study showed people regained about two-thirds of their lost weight within a year of stopping semaglutide.
Whether switching from injectable tirzepatide to oral orforglipron would maintain weight loss is an unanswered question that won't be resolved until we have head-to-head studies.
What should people actually know about GLP-1 alternatives?
If you're looking for alternatives to Mounjaro right now, your options are limited to currently approved medications like semaglutide (Wegovy, Ozempic) or liraglutide (Saxenda).
Don't make treatment decisions based on drugs that aren't available yet. Orforglipron might reach the market in 3-5 years if Phase 3 trials go well and the FDA grants approval.
The promise of an oral GLP-1 drug is real, but it's not ready for patients today.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For TikTok claims FDA approved orforglipron - that's wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Claim verdict
The useful answer behind this video
Claim being checked
Orforglipron is an experimental oral GLP-1 receptor agonist in Phase 2 development by Eli Lilly.
FormBlends verdict
Orforglipron is an experimental oral GLP-1 receptor agonist in Phase 2 development by Eli Lilly. Early results show 12.6% weight loss over 36 weeks, but the drug has not received FDA approval and is years away from market availability.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Orforglipron is an experimental oral GLP-1 receptor agonist in Phase 2 development by Eli Lilly. Early results show 12.6% weight loss over 36 weeks, but the drug has not received FDA approval and is years away from market availability.
- Orforglipron has not been approved by the FDA and remains in early clinical development
- Phase 2 trials showed 12.6% weight loss with orforglipron over 36 weeks, less than tirzepatide's 20.9% in 72 weeks
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- Orforglipron has not been approved by the FDA and remains in early clinical development
- Phase 2 trials showed 12.6% weight loss with orforglipron over 36 weeks, less than tirzepatide's 20.9% in 72 weeks
- The drug's main advantage would be oral administration versus weekly injections for current GLP-1 medications
- No studies have tested orforglipron for weight maintenance after other GLP-1 treatments
- Phase 3 trials are expected to begin in 2024, meaning FDA approval is likely years away
- Currently approved GLP-1 alternatives to Mounjaro include semaglutide and liraglutide
- People typically regain two-thirds of lost weight within a year of stopping GLP-1 treatment
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
NUTRI Letícia Boettcher R. · TikTok creator
20.0K views on this video
Essa semana foi liberado pelo FDA Orfoglipron!!! Um novo medicamento que se liga ao receptor de glp1 e nos estudos mostra ser uma ótima alternativa de manutenção de peso pós Mounjaro!
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by NUTRI Letícia Boettcher R., not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.